Clinlical Effect And Safety Of Pegylated Interferonɑ-2a In The Treatment Of Chronic Hepatitis B

Objective: To evaluate the efficacy ,toleralibity and safety of therapy with pegylated interferon -2a (PEGASYS) in patients with chronic hepatitis B. Methods: 28 patients with HBeAg-positive chronic hepatitis B were all received pegylated interferon -2a (PEGASYS) 180μg/wk lasting for 48 weeks and followed up for 24 weeks.The main pamameters to value the efficacy were virological response and biochemical response.The side effects were intensively observed. Results After 48 weeks treatment , 13/28 patients achieved completely response(46.4%), whereas 11/28 patients (39.3%) obtained sustained response, including one case with negative HBsAg,positive HBsAb contiuely. In the end of therapy, serum ALT of 57.1% patients returned to nomal level, and serum ALT of 71.4% patients returned to nomal level when the following-up was over. ALT in pretreament had no effect on the sustained response rate(P>0.05).There was a significant statistical difference of efficacy in the patients with different early viral load, the sustained response rate of low viral load﹙HBV-DNA<10~5copies/L﹚was 70.0%,while high viral load(HBV-DNA>10~5copies/L)was only 22.2%,P<0.05.The major advers events were fever,leukopenia and thrombocytopenia, and there was no serious advers events. Conclusion The efficacy of pegylated interferon -2a (PEGASYS ) in the treatment of chronic hepatitis B is significant. Pegylated interferon -2a (PEGASYS) has good toleralibity and safety.